Molecular Formula | C78H123N23O23S2 |
Molar Mass | 1815.1 |
Density | 1.49 |
pKa | 3.49±0.10(Predicted) |
Use | The application of AOD9604 is more effective than its predecessor AOD9401 in stimulating lipolysis (fat burning) and antiadipogenic activity. AOD9604 stimulates lipolysis (lipolysis or destruction) and inhibits lipogenesis (prevents the conversion of fatty food materials into body fat), as does growth-induced chemiclosin. |
Abstract:
Metabolic is developing -9604 for the potential treatment of . By February 2002, phase IIa trials were underway.
DOI:
http://dx.doi.org/
cited:
year:
2004
Abstract:
AOD-9604: The anti-depressant making Australian sport a very unhappy place. Abstract: This article looks at the ongoing confusion regarding non-approved substances and the regulatory status of the drug AOD-9604.
Key words:
free magnetic energy space weather forecasting
Meeting Time:
2010
cited:
Abstract:
oral administration of the active peptide AOD9604 (I) is associated with weight loss in obese subjects, according to the results of Phase IIb trials. A total of 300 participants with a body-mass index of 35 or more were randomly assigned to receive different doses of (I) of 1,5,10,20, or 30mg per day or placebo. After 12 weeks, the mean weight loss was 0.8 in the I 1-mg group and in the placebo group, and weight loss was maintained throughout the treatment period. Compared with placebo group
Key words:
placebo Take weight mitigate subject treatment period Different doses Average Hold
year:
2005